



ALTHEA GROUP HOLDINGS LIMITED

(ASX:AGH)

INVESTOR PRESENTATION
SEPTEMBER 2019



Althea™

Choose an Althea™ life

ESTABLISHED

Althea is an Australian licensed producer, supplier and exporter of pharmaceutical grade medicinal cannabis

EDUCATION

Althea is a leading provider of medicinal cannabis education, market access and management services. Althea supports eligible patients and Healthcare Professionals with navigating medicinal cannabis treatment pathways

EXPANSION

Althea operates in highly regulated medicinal cannabis markets, including Australia and the United Kingdom, with expansion opportunities in emerging markets across Europe and Asia

ACCESS MADE SIMPLE

Althea Group Holdings Limited (ASX:AGH)



ALTHEA CONCIERGE: An online platform for patients, doctors and pharmacists to manage their medicinal cannabis needs

KEY MARKET STATISTICS | LISTED ON ASX: 21 SEPTEMBER 2018

Share Price Performance



Key Market Statistics¹

ASX code	AGH
Listing price (Date of listing)	\$0.20
Current Share Price	\$0.790
Market capitalisation	\$184.15m
Shares on issue	233.1m
GISC clarification	Pharmaceutical, Biotechnology & Life Sciences

¹As at 10 September 2019

EXPERIENCED & RELEVANT LEADERSHIP TEAM



Andrew Newbold | Chairman & Independent Non-Executive

- Extensive experience as director of numerous private companies and not-for-profit organisations
- 20 years' experience as a commercial lawyer and has played an integral role in the development of various businesses.



Joshua Fegan | Chief Executive Officer & Founder

- Founder of Althea Group with extensive experience in business building, sales and marketing
- Proven business and strategy skills and previously held numerous senior management roles at national value-based retailer, Strathfield Group



Penny Dobson | Independent Non-Executive Director

- Accomplished business executive in healthcare industry and trained pharmacist in New Zealand, three decades at global pharma Merck & Co, in a variety of commercial roles
- Currently Deputy Chair of the Australian Nuclear Science and Technology Organisation Board, and a non-executive director at Invetus Pty Ltd



Alan Boyd | Independent Non-Executive Director

- Chief Financial Officer and Company Secretary of Ridley Corporation, an ASX-listed provider of high-performance animal nutrition solutions
- Alan has occupied the same position with listed biotechnology companies Avexa Limited and Zenyth Therapeutics Limited



END TO END BUSINESS MODEL ENABLED



- **Fully Licenced:** One of the few companies that has been granted the full suite of licences from Office of Drug Control (ODC) and Agriculture Victoria

Production, Cultivation & Manufacture (ODC)	Right to grow and manufacture medicinal cannabis products
Supply, Import (ODC)	Right to import medicinal cannabis for distribution to patients in Australia
Export (ODC)	Ability to export Althea medicinal cannabis to other jurisdictions
Hemp Cultivation (Agriculture Victoria)	Ability to grow hemp product

- **In market products:** Althea supplies patients with pharmaceutical grade, full spectrum medicinal cannabis products
- **Seed-to-sale certification:** Safety, consistency and quality of Althea medicinal cannabis is ensured through a 509-step quality assurance process
- **Simplifying access to medicinal cannabis products:** Online platform for education, access and management services via *Althea Concierge* – a free service for patients, Healthcare Professionals (HCPs) and pharmacists in target territories




Australian Government
 Department of Health
 Office of Drug Control





ALTHEA CONCIERGE

- Launched September 2018 in Australia and May 2019 in UK
- Proactively engages key stakeholders with Althea. Turning point for HCPs and patients
- New smart phone app launching Q4 2019, featuring:
 - Interactive patient treatment plans
 - Real World Data (RWD) registry that can report on efficacy, safety, QALY and patient reported outcomes
 - Unrivalled patient support



Patients



Find HCPs
Information on
access pathways



HCPs



Complete SAS-B
applications in
under 5 minutes
Access patient
treatment plans



Pharmacists



Dispensing and
product information
for Althea medicinal
cannabis



IMPROVING CLINICAL ACCESS

Education

MEDIC (Medical Education in Cannabinoids) is a free online portal offering evidence-based education and resources for Australian & UK HCPs on medicinal cannabis




Mode of action and efficacy

Safety and clinical considerations

Indications (chronic pain, mental health, CINV, other)

Clinical Studies



Inflammation trial



Inflammatory Bowel Disease (Ulcerative Colitis/Crohn's Disease) trial

Both studies will also investigate the mechanism of action of IP on blood inflammatory and immune cell markers and define the pharmacokinetic profile of IP




MEDICINAL CANNABIS: HISTORY & OUTLOOK IN AUSTRALIA



Increasing Usage & Growing Industry

For doctors, the Therapeutic Goods Administration's (TGA) special access scheme requires an application form to be filled out for each patient, detailing their medical history and justifying why medicinal cannabis is an appropriate treatment



Therapeutic Goods Administration (TGA) TGA SAS B Monthly Application Approvals (Cumulative)

Cannabis on track to become a \$1.2 billion industry over the next 10 years
- Prohibition Partners

The Australian market has clearly overcome early obstacles to patient access and is now in a rapid growth phase
The proportion of the market being addressed, however, is still miniscule. With an estimated addressable market of up to 500,000 in Australia and a current market of only 5,000 Active Patients
- FreshLeaf Analytics



HIGHLIGHTS: ALTHEA IN AUSTRALIA

Approaching Rapid Growth Phase & Increasing Market Share

- 1,974 patients have now been prescribed Althea medicinal cannabis products in Australia
- 303 Healthcare Professionals have prescribed Althea medicinal cannabis
- Althea welcomed 392 new patients in August at a rate of approximately 18 patients per business day, representing the largest number of new patients to be prescribed Althea products in a single month
- Althea has approximately 32% market share in Australia based on active patients*

*Based on Freshleaf Analytics 'Australian Medicinal Cannabis Market Patient, Product and Pricing Analysis Q3 2019' estimate (at p.10) of less than 5,000 active patients; and including Althea's total patient accumulation less inactive patient approximation






MEDICINAL CANNABIS: ALTHEA IN AUSTRALIA


Accelerating Patient & Prescriber Growth



Althea's Accelerating Patient Growth in Australia



Althea's Accelerating Doctor Growth in Australia





PATIENT CASE STUDY: ALTHEA IN AUSTRALIA



Real Patients Using Medicinal Cannabis With Real Results

- A 50-year-old successful senior executive travelling for work slipped on a plane resulting in a significant knee injury. Subsequent treatment included pharmacological interventions such as anticonvulsants, narcotic analgesics, opioid analgesics and benzodiazepines, ketamine infusions and nerve blocks
- None of these treatments provided the desired relief. She was now irritable, in constant pain, struggling to sleep, suffering from depression, anxiety and had significant weight gain. She could no longer work and her husband resigned from his job to become her full-time carer
- The patient's GP initiated a treatment of Althea Champlain. At her 3-week review with her GP, she had substantially reduced her pain and insomnia medications. Her pain changed from a self-reported 9 out of 10, to a 4 out of 10
- She is now hopeful of being able to return to work in some capacity – something that just 1 month ago seemed impossible





GLOBAL GROWTH INITIATIVES





UK & EUROPE: SUMMARY OF PROGRESS TO DATE



MYACCESS CLINICS - LAUNCHED Q3 2019



Althea has launched its own chain of private medical clinics in the UK, branded as MyAccess Clinics

First MyAccess Clinic launched in July 2019 in London with two additional locations in Bristol and Glasgow



LED BY:

- Graham Woodward RNMH FCMI as Clinical Director (23 years experience as a Medical Director), and;
- Sarah Dobbin as Patient Care Manager (previously managed a large Canadian LP's patient care team - serviced over 60,000 patients)
- Dr Chris Blue as Training Consultant (responsible for thousands of prescriptions of medical cannabis in Canada)

DRUG SCIENCE - TWENTY21 PILOT



Drug Science's 'Project TWENTY21' is the UK's first national pilot for medical cannabis aims to enroll 20,000 patients before the end of 2021

Althea has been selected from a limited number of medicinal cannabis companies to supply its range of products to the Pilot's patients

Patient treatment and monitoring will be administered by doctors based in MyAccess Clinics

Potential UK patients will be able to register their interest in participating in the Pilot, which is scheduled to commence in Q4 CY19, via www.myaccessclinics.com

PEAK PROCESSING



Peak applied for one of the Canadian industry's first large-scale (infused) cannabis processor licences

Potential to be a leading contract manufacturer for consumer brands wanting to launch recreational cannabis and CBD wellness products

Market share in a C\$4.34B potential legal recreational cannabis market in Canada

SUMMARY

- **Value added products:** Peak intends to extract, toll process and contract manufacture edibles, drinks and nutraceutical products for the Canadian and international market

ASSETS

- **Market leading expertise:** Peak founders have 20+ years of cannabis experience and have successfully built-out cannabis extraction and manufacturing facilities in Canada
- **Purpose-built facility:** Proposed that Peak will be licenced and equipped to manufacture a range of premium cannabis extract products
- **EU GMP potential:** Peak facility can be upgraded to include EU-GMP certified extraction and manufacturing for medical cannabis production

OPPORTUNITY

- **An underserved cannabis market:** Althea expects that food and beverage companies will want cannabis infused products included in their range in the future

PROPOSED EXTRACTION CAPABILITIES



Raw cannabis extraction

Cannabis extract refinement

Cannabinoid isolation: THC & CBD

Finished goods packaging

Cannabinoid potency testing

Nano-emulsification

Spray drying

The above projected extraction capabilities assume Peak Processing's Canadian cannabis processor licence is granted and Peak commences commercial operations



Althea™

ALTHEA GROUP HOLDINGS LIMITED (ASX:AGH)

ACCESS MADE SIMPLE

Althea Group Holdings Limited (ASX:AGH)
www.althea.life

Althea Group Holdings Limited

Joshua Fegan, CEO & Managing Director
1300 70 20 20 | contact@althea.com.au

Investors: PAC Partners Securities

03 8633 9834 | enquiries@pacpartners.com.au

Media: The Capital Network

Julia Maguire, Executive Director
0419 815 386 | julia@thecapitalnetwork.com.au

Althea Group Holdings Limited

ACN 626 966 943
Registered office: Suite 2, Level 37
360 Elizabeth Street, Melbourne
Victoria, Australia 3000





ALTHEA GROUP HOLDINGS LIMITED



Legal Disclaimer

Althea Group Holdings Limited ACN 626 966 943 (**Company**) has prepared this presentation (**Presentation**) dated 10 September 2019 to provide current and prospective investors in the Company with an update in relation to the Company, its subsidiaries and their activities. The information in this Presentation discusses the Company's operations and product range. It is not intended as a promotion of the Company's products. This Presentation contains summary information about the Company, its subsidiaries and their activities which is current as at the date of this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in the Company or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act 2001 (Cth). This Presentation has not been and will not be filed with or approved by any regulatory authority in Australia, including the Australian Securities and Investments Commission (**ASIC**), or any other jurisdiction. The historical information in this Presentation is, or is based upon, information that has been lodged with the Australian Securities Exchange (**ASX**) and released on the ASX Market Announcements Platform. This Presentation should be read in conjunction with the Company's other periodic and continuous disclosure announcements which are available at www.asx.com.au (Company Code: AGH) or www.althea.com.au.

This Presentation does not constitute and should not be considered as an offer, invitation or recommendation to subscribe for or purchase any security in the Company in any jurisdiction. In particular, this presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company's securities have not been, and will not be, registered under the U.S. Securities Act of 1993 (**Securities Act**) or the securities laws of any state or other jurisdiction in the United States and may not be offered or sold in the United States without registration except in a transaction exempt from, or not subject to, the registration requirements of the Securities Act and any other applicable U.S. State securities laws. Neither this Presentation nor anything contained in it forms the basis of any contract or commitment and no agreement to subscribe for securities will be entered into on the basis of this Presentation. This Presentation does not take into account any recipient's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. The Company is not licensed to provide financial product advice in respect of any security in the Company.

To the maximum extent permitted by law, no representation, warranty or undertaking (express or implied) is made, and no responsibility is accepted by the Company or any of its affiliates, related bodies corporate, partners, shareholders, directors, officers, employees, representatives, consultants or advisers or any other person (Parties) as to the adequacy, accuracy, completeness or reasonableness of any statement or any of the information contained in or referred to in this Presentation or as to any other related matter. To the maximum extent permitted by law, none of the Parties takes any responsibility for any loss or damage suffered as a result of any inadequacy, incompleteness or inaccuracy in any such statement or information. To the maximum extent permitted by law, the Parties do not accept any liability to any person for any direct, indirect or consequential loss or damage arising from the use of this material. This Presentation is not a recommendation by any of the Parties that any recipient invest in the Company.

Past performance information provided in this presentation may not be a reliable indication of future performance. This Presentation contains certain forward-looking statements and comments about future events. Forward-looking statements involve known and unknown risks, significant uncertainties, assumptions, contingencies, and other factors, many of which are outside the control of the Company, are subject to change without notice, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct, and which may cause the actual results or performance of the Company to be materially different from any results or performance expressed or implied by such forward-looking statements. Such forward-looking statements speak only as of the date of this Presentation. Forward looking statements should not be relied on as an indication or guarantee of future performance. No representation, warranty or undertaking is made that any projection, forecast, assumption or estimate contained in this Presentation should or will be achieved. Recipients must conduct their own independent investigation, evaluation and analysis of the matters and data set out in this Presentation, and rely entirely on such investigation and analysis. Recipients must form their own opinion as to whether or not to enter into any arrangements with the Company. The distribution of this document in jurisdictions outside Australia may be restricted by law. If you are outside Australia, you may not be a person to whom an offer of securities in the Company may lawfully be made under the applicable laws in the jurisdiction in which you are situated without registration, lodgment or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. Any such restrictions should be observed. By accepting this Presentation, you agree to be bound by the foregoing limitations and conditions.